Fundraising FoxvenBio Partners — 2020 Investments
6 investments dated 2020 · listed companies and verified rows first · show all
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant Ventures+4 more
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D
Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Co-investors5AM VenturesEcoR1 CapitalRA CapitalWellington ManagementvenBio Global Strategic
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsARCH Venture PartnersForesite Capital8VCAxial VC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.